Abstract: Described herein is a method for assessing disulfide bond reduction potential of a protein of interest comprising the following steps: Providing a cell culture fluid sample comprising mammalian cells expressing a protein of interest at a concentration within the range of between 0.2 g/l to 10 g/l Filtering said cell culture fluid sample over at least one filter Displacing O2 in the filtered cell culture fluid sample Collecting at least one sample of the O2-displaced filtered cell culture fluid sample Separating the proteins in said at least one O2-displaced, filtered cell culture fluid sample according to their size under non-denaturing conditions Determining the disulfide bond reduction potential of the protein of interest.

Abstract: Systems and methods for providing a separate interest rate for an individual transaction are disclosed. A system may provide a service associated with a account having an account balance and an associated first interest rate. The system may include a service device having one or more memory devices storing instructions and one or more processors configured to execute the instructions to perform a separate interest rate service process. The process may include providing a separate interest rate service offer to a client device and receiving a separate interest rate selection from the client device. The process may also include determining a selected portion of the account balance corresponding to an amount to which a second interest rate, different from the first interest rate, is to be applied based on the separate interest rate selection.

Abstract: The present disclosure provides a driving circuit of a display panel and a display device. The driving circuit includes a gate-on-array (GOA) circuit transmitting a scan driving signal to the display panel through a corresponding gate signal line, and further includes a pull-down module and a control bus. The pull-down module is activated at a falling edge of a gate driving signal to accelerate a potential descent speed of the pull-down module, thereby increasing a charging time of a thin film transistor and realizing a narrow-frame display panel.

Abstract: An electrical package can include a substrate having a first side and a second side opposite the first side. One or more electrical components mounted to the substrate, and a plurality of electrically conductive interconnect members can be coupled to the second side of the substrate. At least one of the interconnect members can have an elongated shape with a length that is longer than a width. The interconnect member with the elongated shape positioned can be at or proximate one of the corners. The interconnect members can be arranged as a grid, with first interconnect members each occupying a single grid cell, and second interconnect members each occupying at least two grid cells. The second interconnect members can have a shape of two of the first interconnect members coupled by a bridge portion.

Abstract: An electrical package can include a substrate having a first side and a second side opposite the first side. One or more electrical components mounted to the substrate, and a plurality of electrically conductive interconnect members can be coupled to the second side of the substrate. At least one of the interconnect members can have an elongated shape with a length that is longer than a width. The interconnect member with the elongated shape positioned can be at or proximate one of the corners. The interconnect members can be arranged as a grid, with first interconnect members each occupying a single grid cell, and second interconnect members each occupying at least two grid cells. The second interconnect members can have a shape of two of the first interconnect members coupled by a bridge portion.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: A warehouse picking system and a warehouse picking method are provided. The warehouse picking system includes multiple cargo management stations and a management device. The management device receives multiple orders including at least one cargo, calculates an order score of each order by using an order score function; selects at least one order as a target order according to the order scores so as to determine a target cargo management station adapted for processing the target order; selects a cargo picking box storing at least one cargo in the target order from the cargo picking boxes of the target cargo management station to serve as candidate cargo picking boxes; and determines a target cargo picking box adapted for picking the cargo in the target order according to a workload of cargo picking equipment, a workload of cargo transportation equipment, and a disposition of each candidate cargo picking box.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may monitor paging search spaces that correspond to beams other than a serving beam if a signal to interference plus noise ratio (SINR) of the serving beam does not satisfy a SINR threshold. The UE may stop the monitoring if a paging message in the paging search spaces has been successfully decoded. In some aspects, a UE may determine whether a paging search space that corresponds to a serving beam is a last paging search space in a first paging occasion, after the UE decoded a paging downlink control information and failed to decode a paging physical downlink shared channel on the serving beam. The UE may monitor paging search spaces, in a second paging occasion, that correspond to paging search spaces of the first paging occasion. Numerous other aspects are provided.

Abstract: The present disclosure provides a method for training a feature extraction model, a method for classifying an image and related apparatuses, and relates to the field of artificial intelligence technology such as deep learning and image recognition. The scheme comprises: extracting an image feature of each sample image in a sample image set using a basic feature extraction module of an initial feature extraction model, to obtain an initial feature vector set; performing normalization processing on each initial feature vector in the initial feature vector set using a normalization processing module of the initial feature extraction model, to obtain each normalized feature vector; and guiding training for the initial feature extraction model through a preset high discriminative loss function, to obtain a target feature extraction model as a training result.

Abstract: A method and apparatus for estimating a rotor position of a motor, and a motor control system. The method includes: obtaining a position error signal by injecting a high-frequency signal into a stator winding of the motor; obtaining a load parameter indicating a load of the motor, obtaining a direct-current component disturbance value according to the load parameter and a first preset relationship, obtaining a harmonic component disturbance value according to the load parameter and a second preset relationship, and obtaining an observer parameter value according to the load parameter and a third preset relationship; compensating the position error signal according to the direct-current component disturbance value and the harmonic component disturbance value to obtain a compensated position error signal; adjusting an observer parameter according to the observer parameter value, and adjusting the compensated position error signal through an adjusted observer to obtain the rotor position and a rotor speed.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, L3, E, m1, m2 and * are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may determine that a signal - to-noise ratio (SNR) of one or more communications from a serving cell satisfies an SNR threshold after establishing a New Radio radio resource control (RRC) connection with the serving cell. The UE may transmit a measurement message to the cell based at least in part, on the determining that the SNR of the one or more communications from the serving cell satisfies the SNR threshold. The UE may receive, from the serving cell, a list of one or more neighbor cells based at least in part on the transmitting the measurement message, and establish an RRC connection to a neighbor cell on the list based at least in part on determining that a radio link failure occurred. Numerous other aspects are provided.

Abstract: Technologies related to generating diverse electronic summary documents for a webpage are described herein. A sequence of tokens is extracted from the webpage, and the sequence of tokens is provided to several computer-implemented models. The computer-implemented models output respective sets of candidate assets based upon the sequence of tokens, where the candidate assets are potentially included in an electronic summary document for the webpage. Subsequently, a user query is received, and at least one candidate asset from the candidate assets are selected for inclusion in the electronic summary document based upon the query. Thus, different electronic summary documents can be generated for the webpage when different queries are received.

Abstract: Mixed-plastic-polyethylene composition having a melt flow rate (ISO 1133, 2.16 kg, 190° C.) of from 0.2 to 0.7 g/10 min; and a density of from 956 to 965 kg/m3, preferably from 958 to 964 kg/m3.

Abstract: The present invention relates to a cable jacket composition comprising a multimodal olefin copolymer, said copolymer having density of 0.935-0.960 g/cm3 and MFR2 of 2.2-10.0 g/10 min and said composition having ESCR of at least 2000 hours and a cable shrinkage of 0.70% or lower. The invention further relates to the process for preparing said composition and its use as outer jacket layer for a cable, preferably a communication cable, most preferably a fiber optic cable.

Abstract: A memory system including a memory device of storage transistors organized in multiple memory banks where the memory device interacts with a controller device to perform read and write operations. In some embodiments, the controller device is configured to issue to the memory device a write command and a write termination command, where the write command causing the memory device to initiate a write operation in the memory device and the write termination command causing the memory device to terminate the write operation. In one embodiment, the controller device issues a write abort command as the write termination command to terminate a write operation in progress at a certain memory bank of the memory device in order to issue a read command to read data from the same memory bank. The terminated write operation can resume after the completion of the read operation.

Abstract: The invention concerns an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily.

Abstract: Devices for fabrication of shielded modules. In some embodiments, a carrier assembly can be provided for processing of packaged modules. The carrier assembly can include a plate having a first side that defines a plurality of openings, and an adhesive layer implemented on the first side of the plate. The adhesive layer can define a plurality of openings arranged to substantially match the openings of the plate, with each opening of the adhesive layer being dimensioned such that the adhesive layer is capable of providing an adhesive engagement between an underside perimeter portion of a package and a perimeter portion about the corresponding opening of the first side of the plate.

Abstract: The invention concerns an oral pharmaceutical composition consisting essentially of the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and optionally of one or more pharmaceutically acceptable carriers or excipients for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily. The invention further concerns oral pharmaceutical compositions comprising the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and a therapeutically effective dose of a second active ingredient selected from nintedanib or pirfenidone, wherein these oral pharmaceutical compositions are administered to the patient twice daily.